17.3 Electron Transport Chain, ATP Synthesis & Metabolic Inborn Errors

17.3 Electron Transport Chain, ATP Synthesis & Metabolic Inborn Errors

Independent Study Guide Notice: Independent study guide by OpenExamPrep. This educational resource is developed independently by OpenExamPrep and is not sponsored, endorsed, or affiliated with the National Board of Podiatric Medical Examiners (NBPME) or Meazure Learning.

---

Mitochondrial Architecture & The Chemiosmotic Hypothesis

Oxidative phosphorylation is the final common biochemical pathway of aerobic cellular respiration, taking place within specialized compartments of the mitochondrion. It couples the exergonic transfer of electrons from reducing equivalents (NADH and $FADH_2$) along the Electron Transport Chain (ETC) to the endergonic phosphorylation of ADP to generate ATP.

                    Mitochondrial Compartments & Proton Pumping

     OUTER MEMBRANE: Freely permeable to small molecules (<5 kDa) via Porins
     ────────────────────────────────────────────────────────────────────────────
     INTERMEMBRANE SPACE: HIGH [H⁺] (Acidic pH ~7.0, Positive Charge)
                               ▲            ▲            ▲
                              4 H⁺         4 H⁺         2 H⁺
                               │            │            │
     INNER MEMBRANE:      [Complex I]  [Complex III] [Complex IV]  [Complex V]
     (Cardiolipin-rich;        │            │            │             │
      Impermeable to H⁺)       └──> [CoQ] ──┘──>[Cyt c]──┘             │ H⁺ Flux
                                     ▲                                 ▼
                                [Complex II]                      (ATP Synthase)
     ────────────────────────────────┼─────────────────────────────────┼─────────
     MITOCHONDRIAL MATRIX:      Succinate ──> Fumarate           ADP + Pi ──> ATP
     LOW [H⁺] (Alkaline pH ~7.8, Negative Charge)
     (Houses TCA cycle, Beta-oxidation, PDC, mtDNA, and Ribosomes)

The Chemiosmotic Hypothesis (Peter Mitchell)

The mechanism coupling electron transport to ATP synthesis is defined by the Chemiosmotic Hypothesis:

1. Proton Pumping: As electrons transit down a series of oxidation-reduction complexes embedded in the inner mitochondrial membrane, the free energy released from these exergonic redox reactions drives the active pumping of protons ($H^+$) from the mitochondrial matrix outward into the intermembrane space.
2. Proton-Motive Force ($\Delta p$): Because the inner mitochondrial membrane is strictly impermeable to protons (reinforced by the unique phospholipid cardiolipin), an electrochemical proton gradient is established across the membrane. This proton-motive force consists of two components:
   • Electrical Potential ($\Delta \Psi$): The matrix is negatively charged relative to the positive intermembrane space (~160 to 180 mV).
   • Chemical Gradient ($\Delta pH$): The intermembrane space is slightly acidic (pH ~7.0), while the matrix is alkaline (pH ~7.8).
3. ATP Synthesis: Protons can re-enter the matrix exclusively by passing through the designated proton channel of Complex V (ATP Synthase). The thermodynamic dissipation of this proton gradient drives the mechanical rotation of ATP synthase, phosphorylating ADP and inorganic phosphate ($P_i$) into ATP.

---

The Respiratory Complexes (I through V) & Electron Flow

Electrons donated by NADH and $FADH_2$ traverse four respiratory complexes organized in order of increasing standard reduction potential ($E^{\circ'}$), culminating in the reduction of molecular oxygen to water at Complex IV:

                         Flow of Electrons in the ETC
                         
              NADH ──> [Complex I] ──┐
                       (Pumps 4 H⁺)  │
                                     ├──> [Coenzyme Q] ──> [Complex III] ──> [Cytochrome c]
              FADH2 ─> [Complex II] ─┘   (Ubiquinone)      (Pumps 4 H⁺)      (Mobile Carrier)
                       (Pumps 0 H⁺)                                                │
                                                                                   ▼
                                                                             [Complex IV]
                                                                             (Pumps 2 H⁺)
                                                                                   │
                                                                                   ▼
                                                                            1/2 O2 ──> H2O

1. Complex I (NADH:Ubiquinone Oxidoreductase)

• Accepts two high-energy electrons from matrix NADH, transferring them sequentially to Flavin Mononucleotide (FMN) and a series of Iron-Sulfur (Fe-S) centers, which ultimately reduce lipid-soluble Coenzyme Q (Ubiquinone) to ubiquinol ($QH_2$).
• Proton Translocation: Coupled to the transfer of 2 electrons, Complex I actively pumps 4 protons ($4 H^+$) from the matrix into the intermembrane space.
• Specific Inhibitors: Blocked by the pesticide Rotenone, as well as the barbiturate Amobarbital.

2. Complex II (Succinate Dehydrogenase)

• The only membrane-bound component of the TCA cycle. Catalyzes the oxidation of succinate to fumarate, transferring electrons to enzyme-bound FAD, which funnels them through Fe-S centers to Coenzyme Q.
• Proton Translocation: Pumps ZERO protons ($0 H^+$) because the free-energy change of succinate oxidation is insufficient to drive proton translocation.
• Consequence for ATP Yield: Because electrons from $FADH_2$ bypass Complex I and pump fewer total protons across the membrane, 1 mole of $FADH_2$ yields approximately 1.5 ATP, whereas 1 mole of NADH (entering at Complex I) yields approximately 2.5 ATP.
• Specific Inhibitors: Competitively inhibited by Malonate (structural analog of succinate).

Coenzyme Q (Ubiquinone / CoQ10)

• A small, highly hydrophobic, mobile quinone carrier dissolved within the lipid bilayer of the inner mitochondrial membrane. It accepts electrons from Complex I, Complex II, the glycerol-3-phosphate shuttle, and the electron-transferring flavoprotein (ETF) of fatty acid $\beta$-oxidation, shuttling them to Complex III.

3. Complex III (Cytochrome $bc_1$ Complex / Ubiquinol:Cytochrome c Oxidoreductase)

• Accepts electrons from reduced ubiquinol ($QH_2$) and transfers them through cytochromes $b$, $c_1$, and the Rieske Fe-S center via the specialized two-step Q-Cycle, ultimately transferring single electrons to the mobile carrier Cytochrome c.
• Proton Translocation: Actively pumps 4 protons ($4 H^+$) into the intermembrane space per electron pair.
• Specific Inhibitors: Potently inhibited by Antimycin A (a piscicide/antibiotic).

Cytochrome c

• A small, water-soluble peripheral hemoprotein loosely associated with the outer surface of the inner mitochondrial membrane within the intermembrane space. Serves as a single-electron mobile shuttle between Complex III and Complex IV.
• Dual Role in Apoptosis: In response to intrinsic cellular injury or stress (e.g., DNA damage, ischemia), the pro-apoptotic proteins Bax and Bak oligomerize to form pores in the outer mitochondrial membrane. Cytochrome c leaks into the cytosol, binding Apaf-1 (Apoptotic Protease Activating Factor 1) to form the wheel-like apoptosome, which recruits and activates procaspase-9 to trigger executioner caspase-3 mediated programmed cell death.

4. Complex IV (Cytochrome c Oxidase)

• Contains two heme moieties (cytochromes $a$ and $a_3$) and two copper centers ($Cu_A$ and $Cu_B$). It collects 4 electrons from four reduced Cytochrome c molecules and transfers them to terminal molecular oxygen ($O_2$), reducing it to two molecules of water: $\text{O}_2 + 4H^+ + 4e^- \longrightarrow 2H_2O$
• Proton Translocation: Actively pumps 2 protons ($2 H^+$) into the intermembrane space per pair of electrons transferred.
• Inhibitors of Complex IV: Cyanide ($CN^-$), Carbon Monoxide ($CO$), Sodium Azide ($NaN_3$), and Hydrogen Sulfide ($H_2S$) bind tightly to the heme iron in cytochrome $a_3$, arresting oxygen reduction, collapsing the proton gradient, and halting cellular ATP generation.

5. Complex V (ATP Synthase: $F_0F_1$ Complex)

• A multi-subunit rotary molecular motor consisting of two functional domains:
  • $F_0$ Domain: Hydrophobic, membrane-spanning stalk containing the proton-translocating channel.
  • $F_1$ Domain: Spherical catalytic headpiece projecting into the mitochondrial matrix, composed of $\alpha_3\beta_3$ subunits that catalyze the synthesis of ATP from ADP and $P_i$.
• Protons flowing down their electrochemical gradient through the $F_0$ channel drive the mechanical rotation of the central $\gamma$-stalk, inducing conformational changes in the $F_1$ catalytic heads to forge high-energy phosphoanhydride bonds.
• Specific Inhibitors: Oligomycin binds directly to the $F_0$ subunit, physically occluding the proton channel. Because protons can no longer re-enter the matrix, the electrochemical gradient hyperpolarizes to an intolerable level, creating electrostatic back-pressure that secondarily halts the electron transport chain and oxygen consumption.

---

Inhibitors vs. Chemical Uncouplers of Oxidative Phosphorylation

A pivotal distinction on licensing examinations is differentiating between ETC Inhibitors and Chemical Uncouplers:

               ETC Inhibitors vs. Chemical Uncouplers Comparison

     PARAMETER               ETC INHIBITORS                     CHEMICAL UNCOUPLERS
     ───────────────────────────────────────────────────────────────────────────────
     Primary Target          Specific Complex (I - IV)          Inner Membrane Permeability
     Proton Gradient         COLLAPSES (Pumping Stops)          COLLAPSES (Protons Leak In)
     Oxygen Consumption (O2) HALTS (Blocks Electron Flux)       MAXIMALLY ACCELERATES
     ATP Synthesis           HALTS                              HALTS
     Body Temperature        Normal / Hypothermic               SEVERE HYPERTHERMIA
     Examples                Rotenone, Cyanide, CO, Azide       2,4-DNP, Aspirin, Thermogenin

1. Electron Transport Chain Inhibitors

• Directly block electron transfer at a specific redox complex. Because electron transfer is obligatorily coupled to proton pumping, both proton pumping and oxygen consumption stop completely. ATP synthesis halts because the proton gradient is lost. Tissues switch to anaerobic glycolysis, producing severe lactic acidosis.
• Cyanide Poisoning:
  • Binds ferric ($Fe^{3+}$) heme iron in cytochrome $a_3$ with high affinity, arresting Complex IV.
  • Clinical Presentation: Tissues cannot extract oxygen from the blood. Arterial and venous oxygen saturation remain virtually identical; venous blood appears bright cherry-red. Patients present with headache, vomiting, seizures, lactic acidosis, and an odor of bitter almonds on the breath.
  • Antidote Therapy: Rapid administration of Hydroxocobalamin (binds cyanide to form non-toxic cyanocobalamin, excreted in urine) OR a two-step regimen: Nitrites (Amyl nitrite / Sodium nitrite) to oxidize hemoglobin $Fe^{2+}$ to methemoglobin ($Fe^{3+}$), which avidly traps cyanide away from Complex IV, followed immediately by Sodium Thiosulfate (allowing hepatic rhodanese to convert cyanomethemoglobin into water-soluble thiocyanate).
• Carbon Monoxide (CO) Poisoning:
  • Binds ferrous ($Fe^{2+}$) heme iron in hemoglobin with >200-fold higher affinity than oxygen, causing competitive displacement and an allosteric leftward shift in the oxygen-hemoglobin curve (preventing oxygen delivery to tissues). Additionally, CO directly inhibits Complex IV in mitochondria.
  • Clinical Presentation: Headache, nausea, cherry-red skin coloration, normal $PaO_2$ on routine arterial blood gas, but markedly depressed actual oxygen content and elevated carboxyhemoglobin on co-oximetry. Treated with 100% normobaric or hyperbaric oxygen.

2. Chemical & Physiological Uncouplers

• Mechanism: Increase the proton permeability of the inner mitochondrial membrane, allowing protons in the intermembrane space to leak directly back into the matrix without passing through Complex V (ATP Synthase).
• Metabolic Consequences:
  • The proton gradient is completely dissipated $\rightarrow$ ATP synthesis halts.
  • Freed from the back-pressure of the proton gradient, electron transport down Complexes I through IV accelerates to its maximum possible rate $\rightarrow$ Oxygen consumption ($O_2$) reaches maximal levels.
  • The massive energy of substrate oxidation, no longer captured as ATP, is released entirely as uncontrolled HEAT.
• High-Yield Uncoupling Agents:
  1. 2,4-Dinitrophenol (2,4-DNP): A lipophilic weak acid historically abused as an illicit rapid weight-loss agent. Carries protons across the inner membrane into the matrix. Produces rapid weight loss accompanied by severe, potentially fatal hyperthermia (distinct from the RYR1-mediated anesthetic reaction called malignant hyperthermia), profuse diaphoresis, tachycardia, tachypnea, and severe metabolic acidosis.
  2. High-Dose Salicylates (Aspirin Overdose): In toxic overdoses, aspirin acts as an uncoupler of oxidative phosphorylation. Patients present with hyperthermia, tachypnea, and a classic mixed acid-base disorder (respiratory alkalosis via direct medullary respiratory center stimulation followed by high anion gap metabolic acidosis via uncoupling and accumulation of organic acids).
  3. Thermogenin (Uncoupling Protein 1, UCP-1): Endogenous physiological uncoupling protein expressed in the inner mitochondrial membrane of brown adipose tissue. Protons bypass ATP synthase to generate non-shivering thermogenesis, maintaining core body temperature in human neonates and hibernating mammals.

---

Inborn Errors of Carbohydrate Metabolism: Galactose & Fructose

Inherited enzymatic defects in the metabolic assimilation of dietary disaccharides (lactose from milk; sucrose from cane sugar/fruits) produce severe infantile and pediatric pathology:

                     Metabolism of Galactose and Fructose

     GALACTOSE METABOLISM                          FRUCTOSE METABOLISM
     ────────────────────                          ───────────────────
     Lactose (Milk) ──> Glucose + Galactose        Sucrose (Sugar) ──> Glucose + Fructose
                                     │                                         │
               GALK Deficiency ───X  │ (Galactokinase)   Fructokinase Def. ──X │ (Fructokinase)
               (Mild Cataracts)      ▼                   (Essential Fructosuria)▼
                            Galactose-1-Phosphate                    Fructose-1-Phosphate
                                     │                                         │
               GALT Deficiency ───X  │ (GALT)             Aldolase B Def. ──X  │ (Aldolase B)
               (CLASSIC GALACTOSEMIA)▼                    (HEREDITARY FRUCTOSE)▼
                               UDP-Galactose                            DHAP + Glyceraldehyde
                                     │                                         │
                                     ▼                                         ▼
                              Glucose-1-Phosphate                         Glycolysis

Galactosemia: Classic GALT vs. Galactokinase Deficiency

Dietary lactose is cleaved by intestinal lactase into glucose and galactose. Galactose enters hepatocytes to be phosphorylated:

1. Galactokinase (GALK) Deficiency:
   • Defect: Autosomal recessive deficiency of Galactokinase.
   • Pathophysiology: Galactose cannot be phosphorylated to galactose-1-P. Unphosphorylated galactose accumulates in tissues and is shunted by aldose reductase into galactitol, an osmotically active polyol alcohol.
   • Clinical Presentation: Mild, benign condition. Galactitol accumulates within the lens of the eye, drawing in water and producing bilateral infantile cataracts (loss of red reflex). No liver failure, no renal tubular dysfunction, and no intellectual disability. Galactose is excreted in the urine (positive reducing sugar).
2. Classic Galactosemia (GALT Deficiency):
   • Defect: Autosomal recessive deficiency of Galactose-1-Phosphate Uridylyltransferase (GALT).
   • Pathophysiology: Ingestion of milk/formula leads to severe intracellular accumulation of toxic Galactose-1-Phosphate in hepatocytes, renal tubular cells, and the brain, accompanied by massive galactitol accumulation in the lens.
   • Clinical Presentation: Manifests within days to weeks of starting breast milk or cow's milk formula:
     • Profound failure to thrive, persistent vomiting, diarrhea, and dehydration.
     • Jaundice, hepatomegaly, and liver cirrhosis progressing to hepatic failure.
     • Bilateral "oil-droplet" cataracts.
     • Severe intellectual disability and speech deficits.
     • Pathognomonic Complication: Overwhelming, life-threatening neonatal Escherichia coli sepsis (galactose-1-phosphate impairs leukocyte bactericidal activity).
   • Diagnostic & Treatment: Clinitest detects reducing sugar in urine (glucose-dipstick negative); confirmation via erythrocyte GALT enzyme assay. Treatment: absolute, lifelong elimination of galactose and lactose from the diet.

Fructose Disorders: Essential Fructosuria vs. Hereditary Fructose Intolerance

Dietary sucrose (table sugar) is cleaved by sucrase into glucose and fructose. High-fructose corn syrup, honey, and fruits provide direct dietary fructose:

1. Essential Fructosuria:
   • Defect: Autosomal recessive deficiency of Fructokinase.
   • Clinical Presentation: Completely benign, asymptomatic metabolic anomaly. Fructose cannot be trapped intracellularly and is excreted harmlessly in the urine. Detected incidentally on routine pediatric screening when urine tests positive for reducing substances (Clinitest positive) but negative on glucose oxidase dipsticks.
2. Hereditary Fructose Intolerance (HFI):
   • Defect: Autosomal recessive deficiency of Aldolase B (Fructose-1,6-Bisphosphate Aldolase B).
   • Pathophysiology: Ingested fructose is phosphorylated by fructokinase into Fructose-1-Phosphate (F-1-P), which cannot be cleaved and accumulates rapidly within hepatocytes, renal proximal tubule cells, and enterocytes.
   • Phosphate Trapping Mechanism: Accumulating F-1-P sequesters intracellular inorganic phosphate ($P_i$), causing profound intracellular phosphate depletion. The lack of free $P_i$ inhibits glycogen phosphorylase (completely halting glycogenolysis) and depresses ATP synthesis (inhibiting gluconeogenesis).
   • Clinical Presentation: Symptoms appear classically when an infant is weaned from breast milk/formula and introduced to complementary fruits, fruit juices, honey, or table sugar (around 4 to 6 months of age):
     • Profound, symptomatic hypoglycemia, diaphoresis, tremors, lethargy, and vomiting shortly after fructose ingestion.
     • Hepatosplenomegaly, jaundice, and progressive liver cirrhosis.
     • Proximal renal tubular acidosis (Fanconi syndrome with aminoaciduria, phosphaturia, and metabolic acidosis).
   • Treatment: Strict, permanent dietary exclusion of fructose, sucrose, and sorbitol (sorbitol is metabolized to fructose via sorbitol dehydrogenase).

---

The Pentose Phosphate Pathway & G6PD Deficiency

The Pentose Phosphate Pathway (PPP), also known as the Hexose Monophosphate (HMP) Shunt, is an alternative cytosolic pathway of glucose catabolism that branches from Glucose-6-Phosphate:

• Location & Energy: Occurs entirely in the cytosol; generates zero ATP.
• Two Primary Physiological Functions:
  1. Generation of NADPH: Nicotinamide adenine dinucleotide phosphate is utilized for reductive biosynthesis (fatty acids, cholesterol, bile acids, steroid hormones), the respiratory burst in neutrophils (NADPH oxidase), cytochrome P450 hydroxylation, and the maintenance of reduced glutathione (GSH).
  2. Generation of Ribose-5-Phosphate: Obligate substrate for the de novo biosynthesis of purine and pyrimidine nucleotides (DNA and RNA synthesis).

                    Glutathione Defense Against Oxidative Stress

          [HMP SHUNT: G6PD] ──> Generates NADPH
                                     │
                                     ▼
               Glutathione Reductase: Converts GSSG (Oxidized) ──> 2 GSH (Reduced)
                                                                      │
                                                                      ▼
               Glutathione Peroxidase: Neutralizes H2O2 ────────> 2 H2O
                                       (Protects Erythrocyte Cell Membrane)

The Oxidative & Non-Oxidative Phases

1. Oxidative Phase (Irreversible):
   • Glucose-6-Phosphate Dehydrogenase (G6PD): Oxidizes Glucose-6-P to 6-Phosphoglucono-$\delta$-lactone, generating 1 NADPH. This is the committed, rate-limiting enzyme of the pathway, stimulated by $NADP^+$ and inhibited by NADPH.
   • A second oxidation step by 6-phosphogluconate dehydrogenase yields a second NADPH, $CO_2$, and Ribulose-5-phosphate.
2. Non-Oxidative Phase (Reversible):
   • Interconverts ribulose-5-phosphate into Ribose-5-P (nucleotides) or shunts excess pentoses back into glycolytic intermediates (Fructose-6-P and Glyceraldehyde-3-P).
   • Catalyzed by Transketolase, an enzyme that obligatorily requires Thiamine Pyrophosphate (TPP, Vitamin $B_1$) as a cofactor. Measuring erythrocyte transketolase activity before and after thiamine addition is the clinical gold standard for diagnosing thiamine deficiency.

Glucose-6-Phosphate Dehydrogenase (G6PD) Deficiency

• Genetics & Epidemiology: X-linked recessive disorder; represents the most prevalent red blood cell enzymatic defect worldwide (>400 million individuals). High prevalence in populations of Mediterranean, African, and Middle Eastern ancestry, where carrier females enjoy partial protective resistance against severe malaria caused by Plasmodium falciparum.
• Pathophysiology:
  • Mature erythrocytes possess no mitochondria and no nuclei; the HMP shunt is their sole biological source of NADPH.
  • NADPH is required by Glutathione Reductase to reduce oxidized glutathione disulfide (GSSG) back into two molecules of reduced glutathione (GSH).
  • GSH is used by Glutathione Peroxidase to detoxify hydrogen peroxide ($H_2O_2$) and reactive oxygen species into harmless water ($2\text{GSH} + \text{H}_2\text{O}_2 \longrightarrow \text{GSSG} + 2\text{H}_2\text{O}$).
  • When G6PD is deficient, erythrocytes cannot replenish GSH. Exposure to oxidative stress causes hydrogen peroxide to oxidize the sulfhydryl groups of hemoglobin, causing hemoglobin to denature, cross-link, and precipitate into insoluble intracellular inclusions termed Heinz bodies.
  • As erythrocytes traverse the narrow endothelial slits of the splenic red pulp, resident macrophages pluck out the rigid Heinz bodies, excising a portion of the red cell membrane to yield pathognomonic bite cells (degmacytes). The damaged, deformed erythrocytes undergo acute intravascular and extravascular hemolysis.
• Clinical Triggers of Acute Hemolytic Episodes:
  1. Infections: The most common clinical trigger (activated neutrophils generate massive $H_2O_2$ in the oxidative respiratory burst, which diffuses into erythrocytes).
  2. Medications:
     • Antibiotics: Sulfonamides (Trimethoprim-sulfamethoxazole), Nitrofurantoin.
     • Antimycobacterial / Dermatological: Dapsone.
     • Antimalarials: Primaquine, Chloroquine.
     • Others: Rasburicase, high-dose Aspirin.
  3. Foods: Ingestion of Fava beans (Favism; contains the oxidizing glucosides vicine and convicine; most severe in the Mediterranean G6PD variant).
• Clinical Presentation: Two to three days following exposure to an oxidative trigger, the patient develops sudden fatigue, pallor, scleral icterus, dark red-brown "cola-colored" urine (hemoglobinuria), and back/flank pain. Laboratory evaluation reveals normocytic anemia, elevated reticulocyte count, indirect hyperbilirubinemia, elevated serum LDH, and severely depressed serum haptoglobin.
• Diagnostic Pitfall: G6PD enzyme levels can test falsely normal during an acute hemolytic crisis because older, enzyme-depleted erythrocytes have already lysed, leaving behind younger reticulocytes with higher basal G6PD activity. Confirmatory testing must be repeated 2 to 3 months following resolution of the acute hemolytic episode.